Compound class:
Synthetic organic
Comment: SNX281 is a systemically active stimulator of interferon genes (STING) agonist, that was developed to induce anti-tumour immunity [1]. SNX281 is competitive with the endogenous cyclic dinucleotide STING agonist 2'3'-cGAMP. Analysis reveals that SNX281 self-dimerises to generate a structure that is large enough to occupy STING's cyclic dinucleotide binding site, which switches the protein to its active state conformation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
SNX281 has been advanced as a clinical lead for solid tumours and lymphoma. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04609579 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Phase 1 Interventional | Stingthera, Inc. | In this study, SNX281 will be evaluated as a monotherapy and in combination with the immune checkpoint inhibitor |